[ad_1]
According to the report, the first phase of the study, which involved 216 people, found that despite the lack of serious side effects, antibodies developed in vaccinated organisms interfere with the diagnosis of HIV and lead to erroneous results for the virus.
In light of this, CSL, together with the Australian government, decided to discontinue further testing of these vaccines.
“This result reveals risks in the early stages of vaccine development,” said Andrew Nash, CSL’s principal research expert.
He said the Australian COVID-19 vaccine could be improved, but it could take up to 12 months.
CSL plans to produce another 20 million. AstraZeneca has developed doses of the vaccine in addition to the 30 million that are already in production. Therefore, the Australian government intends to increase the order for Novavax.
It was previously announced that the American biotech company Novavax has signed a preliminary agreement with the Australian government. Set the conditions for 40 million. COVID-19 Vaccine Dosage Supply.
[ad_2]
